Arcturus Therapeutics announced the nomination of its first development candidate, ARCT-810, to treat ornithine transcarbamylase deficiency, or OTCD. OTCD is the most common urea cycle disorder. Urea cycle disorders are a group of inherited metabolic disorders that make it difficult for afflicted patients to remove toxic waste products, as proteins are digested. ARCT-810 is based on Arcturus’s propriety lipid library which utilizes the company’s Lunar delivery platform to safely and effectively deliver OTC messenger RNA to liver cells.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.